Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma
NCT03202628
Completed
This phase II trial studies how well ixazomib citrate, pomalidomide, dexamethasone, and stem cell transplantation works in treating patients with multiple myeloma that has come back or does not respond to treatment. Giving chemotherapy, such as pomalidomide and dexamethasone, before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient?s bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected fro... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/01/2023
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma
NCT03201250
Terminated
In the currently proposed phase I/II study, the investigators aim to treat patients with relapsed and/or relapsed refractory Multiple Myeloma who have progressed on carfilzomib-based therapy with an FDA approved c-MET inhibitor, cabozantinib.
Gender:
ALL
Ages:
19 years and above
Trial Updated:
08/25/2023
Locations: University of Nebraska Medical Center, Omaha, Nebraska +1 locations
Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Register for Updates
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
NCT02755597
Completed
This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/18/2023
Locations: Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 156524, Aurora, Colorado +96 locations
Conditions: Relapsed/Refractory Multiple Myeloma
Register for Updates
Spinal Fusions Steroid Study
NCT05287035
Enrolling By Invitation
Current efforts to improve pain alleviation focus on non-opioid pharmaceuticals. Intravenous perioperative corticosteroid administration has been suggested as an alternative method for post-operative pain control. The evidence regarding perioperative intravenous corticosteroids to help alleviate post-operative pain is mixed. Some meta-analyses report decreased opioid consumption and decreased pain intensity after a variety of surgical procedures. However, a study of larger orthopedic procedures... Read More
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
08/17/2023
Locations: Dell Children's Medical Center, Austin, Texas
Conditions: Spinal Fusion
Register for Updates
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
NCT00039130
Completed
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the numbers of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combinin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/16/2023
Locations: Naval Medical Center - San Diego, San Diego, California +30 locations
Conditions: Leukemia, Lymphoma
Register for Updates
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
NCT04119336
Terminated
This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +1 locations
Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.
NCT04208516
Terminated
A multimodal analgesic regimen including regional anesthesia is used at UPMC Shadyside for primary thoracic and major abdominal surgeries. The current standard-of-care regional anesthesia techniques include Erector Spinae Plane (ESP) block for video assisted thorascopic surgery (VATS) and Quadratus Lumborum (QL) block for major abdominal surgery. These blocks are routinely administered as a continuous catheter technique in order to extend the duration of postoperative analgesia. Although rare, c... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/15/2023
Locations: UPMC Shadyside Hospital, Pittsburgh, Pennsylvania
Conditions: Postoperative Pain
Register for Updates
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
NCT05205252
Withdrawn
This trial will study how safely the tazemetostat works with other therapies in various hematological malignancies. Hematologic malignancies are cancers that most often begin in the bone marrow or lymph nodes where blood precursors are produced. They are often called blood cancers and fall into three categories: leukemia, lymphoma and myeloma. Tazemetostat has been found to be a safe and effective drug that works in patients with follicular lymphoma where the disease has come back after treatm... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/11/2023
Locations: California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California +2 locations
Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
Register for Updates
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT02514382
Completed
This phase Ib trial studies the safety and best dose of wild-type reovirus in combination with bortezomib and dexamethasone and to see how well they work in treating patients with multiple myeloma that has returned (relapsed) or does not respond to treatment (refractory). A virus, called wild-type reovirus, may be able to infect cancer cells and slow the cancer growth and kill cancer cells. Bortezomib and dexamethasone may stop the growth of cancer cells by blocking some of the enzymes needed fo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2023
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
NCT00101101
Completed
RATIONALE: Vaccines made from gene-modified cells and a person's cancer cells may make the body build an effective immune response to kill cancer cells. Interleukin-2 (IL-2) may stimulate the white blood cells to kill cancer cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving m... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/04/2023
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Lymphoma
Register for Updates
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
NCT00078949
Completed
RATIONALE: Drugs used in chemotherapy, such as dexamethasone, cisplatin, gemcitabine, and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal... Read More
Gender:
ALL
Ages:
Between 16 years and 65 years
Trial Updated:
08/03/2023
Locations: Rush-Presbyterian-St. Luke's Medical Centre, Chicago, Illinois +26 locations
Conditions: Lymphoma
Register for Updates
Antibiotic Concentration After Delivery to Middle Ear for Chronic Suppurative Otitis Media
NCT05133258
Completed
The study team aims to elucidate the potential role of ototopical antibiotic concentration on outcomes in patients diagnosed with chronic suppurative otitis media (CSOM). Chronic suppurative otitis media (CSOM) is characterized by chronic inflammation of the middle ear with persistent discharge from a non-intact tympanic membrane. CSOM is notably associated with a significant burden of disease worldwide. Topical fluoroquinolones are first line therapy for CSOM and are advantageous as compared to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2023
Locations: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Chronic Suppurative Otitis Media
Register for Updates